A phase II trial investigating the safety and efficacy of MART-1 TCR transgenic lymphocytes and MART-1 peptide-pulsed dendritic cell (DC) vaccination double therapy in patients with metastatic melanoma was conducted (NCT00910650). This evidence concerns the gene MLANA and metastatic melanoma.